{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T20:58:54Z","timestamp":1790369934473,"version":"4.1.0"},"reference-count":85,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:p>B-cell maturation antigen (BCMA) targeted chimeric antigen receptor T-cell (CAR-T) cell therapy has proven highly efficacious for relapsed multiple myeloma, inducing deep and durable remissions. Recent reporting has bolstered significant enthusiasm, describing upwards of one-third of patients in continued remission, 5 years following BCMA CAR-T without receiving any subsequent therapy, suggesting the possibility that this treatment may offer the hope of a cure. There are many well-characterized side effects from CAR-T, and mitigation strategies have been established to make this therapy safe. However, as the use of CAR-T cells has become more widespread, several novel and unanticipated side effects have emerged. These novel toxicities of CAR-T can be delayed, occurring within the first 3 to 6 months, and can be life-threatening or life-altering. Thus, early detection and timely management are essential. This comprehensive review will cover the diagnosis and management of common and emerging toxicities associated with CAR T-cell therapy for multiple myeloma.<\/jats:p>","DOI":"10.1097\/ppo.0000000000000849","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T20:00:55Z","timestamp":1790366455000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Managing Novel CAR T-Cell Toxicities in Multiple Myeloma"],"prefix":"10.1097","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-4373-2332","authenticated-orcid":false,"given":"Kwan-Keat","family":"Ang","sequence":"first","affiliation":[{"name":"Division of Hematology and Oncology, University of California San Francisco, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jodi","family":"Lipof","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, University of California San Francisco, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anupama","family":"Kumar","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, University of California San Francisco, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lekha","family":"Mikkilineni","sequence":"additional","affiliation":[{"name":"Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred","family":"Chung","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, University of California San Francisco, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shagun","family":"Arora","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, University of California San Francisco, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Sayre","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, University of California San Francisco, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Wolf","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, University of California San Francisco, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajai","family":"Chari","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, University of California San Francisco, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Martin","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, University of California San Francisco, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren","family":"Pan","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, University of California San Francisco, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,9]]},"reference":[{"key":"R1-20260925","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1200\/JCO-25-00760","article-title":"Long-Term (\u22655-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed\/Refractory Multiple Myeloma","volume":"43","author":"Jagannath","year":"2025","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"R2-20260925","doi-asserted-by":"crossref","first-page":"8009","DOI":"10.1200\/JCO.2023.41.16_suppl.8009","article-title":"CARTITUDE-1 final results: Phase 1b\/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed\/refractory multiple myeloma","volume":"41","author":"Lin","year":"2023","journal-title":"J Clin Oncol"},{"key":"R3-20260925","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"The Lancet"},{"key":"R4-20260925","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41408-022-00629-1","article-title":"Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies","volume":"12","author":"Cohen","year":"2022","journal-title":"Blood Cancer J"},{"key":"R5-20260925","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/s41408-025-01410-w","article-title":"Clinical experience with cranial nerve palsy in patients infused with ciltacabtagene autoleucel for the treatment of relapsed\/refractory MM in CARTITUDE-1, -2, and -4","volume":"15","author":"Rodr\u00edguez-Otero","year":"2025","journal-title":"Blood Cancer J"},{"key":"R6-20260925","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"New England Journal of Medicine"},{"key":"R7-20260925","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2209900","article-title":"GPRC5D-Targeted CAR T Cells for Myeloma","volume":"387","author":"Mailankody","year":"2022","journal-title":"New England Journal of Medicine"},{"key":"R8-20260925","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/s41408-026-01496-w","article-title":"Safety and efficacy of ciltacabtagene autoleucel for relapsed\/refractory multiple myeloma: a CIBMTR study","volume":"16","author":"Hansen","year":"2026","journal-title":"Blood Cancer J [Internet]"},{"key":"R9-20260925","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.3390\/cancers18061013","article-title":"Real-World Experience with Approved CAR T-Cell Therapies Ciltacabtagene Autoleucel and Idecabtagene Vicleucel in 1272 Relapsed\/Refractory Multiple Myeloma Patients","volume":"18","author":"Filippatos","year":"2026","journal-title":"Cancers (Basel)"},{"key":"R10-20260925","doi-asserted-by":"crossref","first-page":"e798","DOI":"10.1016\/S2352-3026(25)00176-0","article-title":"GPRC5D-targeted CAR T-cell therapy (CT071) in patients with relapsed or refractory multiple myeloma: a first-in-human, single-centre, single-arm, phase 1 trial","volume":"12","author":"Jin","year":"2025","journal-title":"The Lancet Haematology"},{"issue":"16_suppl","key":"R11-20260925","doi-asserted-by":"crossref","first-page":"TPS7564","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS7564","article-title":"QUINTESSENTIAL-2: A phase 3 study comparing efficacy and safety of arlocabtagene autoleucel (arlo-cel) versus standard regimens in adult patients with relapsed or refractory multiple myeloma (RRMM) refractory to lenalidomide","volume":"43","author":"Popat","year":"2025","journal-title":"J Clin Oncol"},{"key":"R12-20260925","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"New England Journal of Medicine"},{"key":"R13-20260925","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASBMT Consensus Grading for Cytokine Release Syndrome and Neurological Toxicity Associated with Immune Effector Cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"R14-20260925","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.jaci.2020.07.025","article-title":"Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies","volume":"146","author":"Freyer","year":"2020","journal-title":"Journal of Allergy and Clinical Immunology"},{"key":"R16-20260925","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discov"},{"key":"R17-20260925","doi-asserted-by":"crossref","first-page":"3978","DOI":"10.1200\/JCO.21.01992","article-title":"Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline","volume":"39","author":"Santomasso","year":"2021","journal-title":"J Clin Oncol"},{"key":"R18-20260925","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","article-title":"Toxicities of chimeric antigen receptor T cells: recognition and management","volume":"127","author":"Brudno","year":"2016","journal-title":"Blood"},{"key":"R19-20260925","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1007\/s00415-020-10237-3","article-title":"Neurological updates: neurological complications of CAR-T therapy","volume":"268","author":"Tallantyre","year":"2021","journal-title":"J Neurol"},{"key":"R20-20260925","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1093\/brain\/awz053","article-title":"Neurological toxicities associated with chimeric antigen receptor T-cell therapy","volume":"142","author":"Rubin","year":"2019","journal-title":"Brain"},{"key":"R21-20260925","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1007\/s40263-018-0582-9","article-title":"Neurotoxicity Associated with CD19-Targeted CAR-T Cell Therapies","volume":"32","author":"Gust","year":"2018","journal-title":"CNS Drugs"},{"key":"R22-20260925","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"R23-20260925","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1007\/s00134-020-06193-1","article-title":"Acute life-threatening toxicity from CAR T-cell therapy","volume":"46","author":"Azoulay","year":"2020","journal-title":"Intensive Care Med"},{"key":"R24-20260925","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/ana.25502","article-title":"Glial injury in neurotoxicity after pediatric CD19-directed chimeric antigen receptor T cell therapy","volume":"86","author":"Gust","year":"2019","journal-title":"Annals of Neurology"},{"key":"R25-20260925","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1001\/jama.2024.19462","article-title":"CAR T Cells and T-Cell Therapies for Cancer: A Translational Science Review","volume":"332","author":"Brudno","year":"2024","journal-title":"JAMA"},{"key":"R26-20260925","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.1182\/bloodadvances.2020002509","article-title":"Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies","volume":"4","author":"Jain","year":"2020","journal-title":"Blood Adv"},{"key":"R27-20260925","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1038\/s41409-019-0487-3","article-title":"Early and late hematologic toxicity following CD19 CAR-T cells","volume":"54","author":"Fried","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"R28-20260925","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1182\/bloodadvances.2020004142","article-title":"Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR T-cell therapy","volume":"6","author":"Juluri","year":"2022","journal-title":"Blood Advances"},{"key":"R29-20260925","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1080\/10428194.2022.2056172","article-title":"Acute and delayed cytopenias following CAR T-cell therapy: an investigation of risk factors and mechanisms","volume":"63","author":"Brudno","year":"2022","journal-title":"Leuk Lymphoma"},{"key":"R30-20260925","doi-asserted-by":"crossref","first-page":"101158","DOI":"10.1016\/j.xcrm.2023.101158","article-title":"Prolonged cytopenia following CD19 CAR T cell therapy is linked with bone marrow infiltration of clonally expanded IFN\u03b3-expressing CD8 T cells","volume":"4","author":"Strati","year":"2023","journal-title":"Cell Rep Med"},{"key":"R31-20260925","first-page":"2460","article-title":"How I treat cytopenias after CAR T-cell therapy","volume":"141","author":"Jain","year":"2023","journal-title":"Blood"},{"key":"R32-20260925","doi-asserted-by":"crossref","first-page":"4690","DOI":"10.1158\/1078-0432.CCR-24-1798","article-title":"Second primary malignancies after CAR T-cell therapy: A systematic review and meta-analysis of 5,517 lymphoma and myeloma patients","volume":"30","author":"Tix","year":"2024","journal-title":"Clin Cancer Res"},{"key":"R33-20260925","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1182\/blood.2020010543","article-title":"CAR-HEMATOTOX: a model for CAR T-cell\u2013related hematologic toxicity in relapsed\/refractory large B-cell lymphoma","volume":"138","author":"Rejeski","year":"2021","journal-title":"Blood"},{"issue":"Suppl 1","key":"R34-20260925","doi-asserted-by":"crossref","first-page":"7506","DOI":"10.1182\/blood-2022-165266","article-title":"The CAR-Hematotox Score As a Prognostic Model of Toxicity and Response in Patients Receiving BCMA-Directed CAR-T for Relapsed\/Refractory Multiple Myeloma","volume":"140","author":"Rejeski","year":"2022","journal-title":"Blood"},{"key":"R35-20260925","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","article-title":"CAR T cell\u2013induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade","volume":"24","author":"Giavridis","year":"2018","journal-title":"Nat Med"},{"key":"R36-20260925","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1182\/blood.2023020578","article-title":"Immune effector cell\u2013associated hematotoxicity: EHA\/EBMT consensus grading and best practice recommendations","volume":"142","author":"Rejeski","year":"2023","journal-title":"Blood"},{"issue":"Suppl 1","key":"R37-20260925","doi-asserted-by":"crossref","first-page":"4712","DOI":"10.1182\/blood-2024-204257","article-title":"Efficacy of Stem Cell Boost (SCB) for Chimeric Antigen Receptor T Cell (CAR-T)-Related Hematologic Toxicity in Patients with Relapsed\/Refractory Multiple Myeloma (RRMM)- a Multi-Center Real World Experience","volume":"144","author":"Varga","year":"2024","journal-title":"Blood"},{"key":"R38-20260925","doi-asserted-by":"crossref","first-page":"4715","DOI":"10.1182\/bloodadvances.2022007572","article-title":"CD34+-selected stem cell boost can safely improve cytopenias following CAR T-cell therapy","volume":"6","author":"Mullanfiroze","year":"2022","journal-title":"Blood Advances"},{"key":"R39-20260925","doi-asserted-by":"crossref","first-page":"4719","DOI":"10.1182\/bloodadvances.2022007776","article-title":"Safety and feasibility of stem cell boost as a salvage therapy for severe hematotoxicity after CD19 CAR T-cell therapy","volume":"6","author":"Rejeski","year":"2022","journal-title":"Blood Advances"},{"key":"R40-20260925","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.hoc.2025.02.005","article-title":"Immune Effector Cell-associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS)","volume":"39","author":"Lee","year":"2025","journal-title":"Hematology\/Oncology Clinics of North America"},{"key":"R41-20260925","doi-asserted-by":"crossref","first-page":"5149","DOI":"10.3390\/cancers15215149","article-title":"Immune Effector Cell-Associated HLH-like Syndrome: A Review of the Literature of an Increasingly Recognized Entity","volume":"15","author":"Fugere","year":"2023","journal-title":"Cancers (Basel)"},{"key":"R42-20260925","first-page":"438.e1","article-title":"Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome","volume":"29","author":"Hines","year":"2023","journal-title":"Transplantation and Cellular Therapy, Official Publication of the American Society for Transplantation and Cellular Therapy"},{"key":"R43-20260925","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1158\/2643-3230.BCD-21-0203","article-title":"Potential Role of IFN\u03b3 Inhibition in Refractory Cytokine Release Syndrome Associated with CAR T-cell Therapy","volume":"3","author":"McNerney","year":"2022","journal-title":"Blood Cancer Discov"},{"key":"R44-20260925","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1182\/bloodadvances.2022008256","article-title":"Interferon-\u03b3 blockade in CAR T-cell therapy\u2013associated macrophage activation syndrome\/hemophagocytic lymphohistiocytosis","volume":"7","author":"Rainone","year":"2023","journal-title":"Blood Adv"},{"key":"R45-20260925","doi-asserted-by":"crossref","first-page":"3493","DOI":"10.1182\/blood.2021014860","article-title":"A study of ruxolitinib response\u2013based stratified treatment for pediatric hemophagocytic lymphohistiocytosis","volume":"139","author":"Zhang","year":"2022","journal-title":"Blood"},{"key":"R46-20260925","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.2217\/imt-2020-0116","article-title":"Adjuvant Ruxolitinib Therapy Relieves Steroid-Refractory Cytokine-Release Syndrome without Impairing Chimeric Antigen Receptor-Modified T-Cell Function","volume":"12","author":"Wei","year":"2020","journal-title":"Immunotherapy"},{"key":"R47-20260925","article-title":"The Current Landscape of Secondary Malignancies after CAR T-Cell Therapies: How Could Malignancies Be Prevented?","author":"Bouziana","journal-title":"International Journal of Molecular Sciences [Internet]"},{"key":"R48-20260925","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1038\/mt.2013.67","article-title":"Mature T-cell Lymphomagenesis Induced by Retroviral Insertional Activation of Janus Kinase 1","volume":"21","author":"Heinrich","year":"2013","journal-title":"Mol Ther"},{"key":"R49-20260925","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1038\/s41591-024-02826-w","article-title":"T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy","volume":"30","author":"Ghilardi","year":"2024","journal-title":"Nat Med"},{"key":"R50-20260925","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1182\/blood.2021010813","article-title":"Development of CAR T-cell lymphoma in 2 of 10 patients effectively treated with piggyBac-modified CD19 CAR T cells","volume":"138","author":"Bishop","year":"2021","journal-title":"Blood"},{"key":"R51-20260925","doi-asserted-by":"crossref","first-page":"4333","DOI":"10.1158\/1078-0432.CCR-25-1587","article-title":"Clonal Hematopoiesis and Inflammation Predict Hematologic Toxicity and Secondary Myeloid Malignancies after B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-cell Therapy","volume":"31","author":"Avigan","year":"2025","journal-title":"Clin Cancer Res"},{"key":"R52-20260925","article-title":"FDA Investigating Serious Risk of T-cell Malignancy Following BCMA-Directed or CD19-Directed Autologous Chimeric Antigen Receptor (CAR) T cell Immunotherapies","journal-title":"FDA [Internet]"},{"key":"R53-20260925","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJMp2400209","article-title":"Secondary Cancers after Chimeric Antigen Receptor T-Cell Therapy","volume":"390","author":"Verdun","year":"2024","journal-title":"New England Journal of Medicine"},{"key":"R54-20260925","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/s41408-024-01167-8","article-title":"Immune effector cell-associated enterocolitis following chimeric antigen receptor T-cell therapy in multiple myeloma","volume":"14","author":"Fortuna","year":"2024","journal-title":"Blood Cancer J"},{"issue":"2, Suppl","key":"R55-20260925","doi-asserted-by":"crossref","first-page":"S417","DOI":"10.1016\/j.jtct.2025.12.598","article-title":"Immune-Effector Cell-Associated Enteritis\/Colitis (IEC-EC) after Ciltacabtagene Autoleucel (cilta-cel) in Multiple Myeloma (MM): Updated Clinicopathologic Data and Management","volume":"32","author":"Mikkilineni","year":"2026","journal-title":"Transplantation and Cellular Therapy"},{"key":"R56-20260925","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1182\/blood-2016-04-711903","article-title":"T cells expressing an anti\u2013B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma","volume":"128","author":"Ali","year":"2016","journal-title":"Blood"},{"issue":"Suppl 1","key":"R57-20260925","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1182\/blood-2020-134322","article-title":"Efficacy and Safety of Idecabtagene Vicleucel (ide-cel, bb2121) in Elderly Patients with Relapsed and Refractory Multiple Myeloma: KarMMa Subgroup Analysis","volume":"136","author":"Berdeja","year":"2020","journal-title":"Blood"},{"issue":"Supplement 1","key":"R58-20260925","doi-asserted-by":"crossref","first-page":"4846","DOI":"10.1182\/blood-2024-207885","article-title":"Indolent CD8+ CAR T-Cell Lymphoma of the Gastrointestinal Tract after Ciltacabtagene Autoleucel Therapy for Relapsed\/Refractory Multiple Myeloma","volume":"144","author":"Hosoya","year":"2024","journal-title":"Blood"},{"key":"R59-20260925","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1056\/NEJMoa2401530","article-title":"Indolent CD4+ CAR T-Cell Lymphoma after Cilta-cel CAR T-Cell Therapy","volume":"390","author":"Ozdemirli","year":"2024","journal-title":"N Engl J Med"},{"key":"R60-20260925","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1056\/NEJMoa2411507","article-title":"CD4+ T-Cell Lymphoma Harboring a Chimeric Antigen Receptor Integration in TP53","volume":"392","author":"Perica","year":"2025","journal-title":"New England Journal of Medicine"},{"issue":"Suppl 1","key":"R61-20260925","doi-asserted-by":"crossref","first-page":"6939","DOI":"10.1182\/blood-2023-178806","article-title":"CAR+ T-Cell Lymphoma Post Ciltacabtagene Autoleucel Therapy for Relapsed Refractory Multiple Myeloma","volume":"142","author":"Harrison","year":"2023","journal-title":"Blood"},{"issue":"3, Suppl","key":"R62-20260925","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jtct.2026.02.014","article-title":"D-Domain Binder In Anitocabtagene Autoleucel Shows Absence of Tonic Signaling and Cross-Reactivity Profile","volume":"32","author":"Witter","year":"2026","journal-title":"Transplantation and Cellular Therapy"},{"key":"R63-20260925","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1182\/blood.2025032347","article-title":"Ruxolitinib for Ciltacabtagene Autoleucel\u2013Associated Refractory Diarrhea","volume":"147","author":"Blumenberg","year":"2026","journal-title":"Blood [Internet]"},{"key":"R64-20260925","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1158\/1078-0432.CCR-24-0378","article-title":"FDA Approval Summary: Ciltacabtagene Autoleucel for Relapsed or Refractory Multiple Myeloma","volume":"30","author":"Natrajan","year":"2024","journal-title":"Clin Cancer Res"},{"key":"R65-20260925","doi-asserted-by":"crossref","first-page":"e203","DOI":"10.1016\/S1470-2045(24)00715-0","article-title":"Non-ICANS neurological complications after CAR T-cell therapies: recommendations from the EBMT Practice Harmonisation and Guidelines Committee","volume":"26","author":"Graham","year":"2025","journal-title":"The Lancet Oncology"},{"issue":"Suppl 1","key":"R66-20260925","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1182\/blood-2023-178743","article-title":"Clinical Experience with Cranial Nerve Impairment in the CARTITUDE-1, CARTITUDE-2 Cohorts A, B, and C, and Cartitude-4 Studies of Ciltacabtagene Autoleucel (Cilta-cel)","volume":"142","author":"Van De Donk","year":"2023","journal-title":"Blood"},{"key":"R67-20260925","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1182\/blood.2024025679","article-title":"Clinical features, pathophysiology, and management of acute myelopathy following CAR T-cell therapy","volume":"144","author":"Desch\u00eanes-Simard","year":"2024","journal-title":"Blood"},{"key":"R68-20260925","doi-asserted-by":"crossref","first-page":"e006059","DOI":"10.1136\/jitc-2022-006059","article-title":"Diabetes insipidus and Guillain-Barr\u00e9-like syndrome following CAR-T cell therapy: a case report","volume":"11","author":"Koch","year":"2023","journal-title":"J Immunother Cancer"},{"key":"R69-20260925","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1038\/s41591-021-01564-7","article-title":"Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy","volume":"27","author":"Van Oekelen","year":"2021","journal-title":"Nat Med"},{"key":"R70-20260925","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1182\/blood.2023021860","article-title":"BCMA-CAR T-cell treatment\u2013associated parkinsonism","volume":"142","author":"Gust","year":"2023","journal-title":"Blood"},{"key":"R71-20260925","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1182\/blood.2024025945","article-title":"Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed\/refractory multiple myeloma","volume":"145","author":"Sidana","year":"2025","journal-title":"Blood"},{"key":"R72-20260925","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1182\/blood.2024026216","article-title":"Standard-of-care idecabtagene vicleucel for relapsed\/refractory multiple myeloma","volume":"146","author":"Sidana","year":"2025","journal-title":"Blood"},{"issue":"Suppl 1","key":"R73-20260925","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1182\/blood-2024-198499","article-title":"Phase 2 Registrational Study of Anitocabtagene Autoleucel for the Treatment of Patients with Relapsed and\/or Refractory Multiple Myeloma: Preliminary Results from the IMMagine-1 Trial","volume":"144","author":"Freeman","year":"2024","journal-title":"Blood"},{"key":"R74-20260925","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1182\/blood.2023021429","article-title":"Chemotherapy-induced reversal of ciltacabtagene autoleucel\u2013associated movement and neurocognitive toxicity","volume":"142","author":"Graham","year":"2023","journal-title":"Blood"},{"key":"R75-20260925","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/nature11405","article-title":"An anatomically comprehensive atlas of the adult human brain transcriptome","volume":"489","author":"Hawrylycz","year":"2012","journal-title":"Nature"},{"issue":"Suppl 1","key":"R76-20260925","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1182\/blood-2024-201356","article-title":"Efficacy and Safety with Extended Follow-up in a Phase 1 Study of BMS-986393, a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted CAR T Cell Therapy, in Patients (pts) with Heavily Pretreated Relapsed\/Refractory (RR) Multiple Myeloma (MM)","volume":"144","author":"Bal","year":"2024","journal-title":"Blood"},{"key":"R77-20260925","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.seminhematol.2023.02.003","article-title":"Infectious Complications of Chimeric Antigen Receptor (CAR) T-Cell Therapies","volume":"60","author":"Gea-Banacloche","year":"2023","journal-title":"Semin Hematol"},{"key":"R78-20260925","doi-asserted-by":"crossref","first-page":"100596","DOI":"10.1016\/j.blre.2019.100596","article-title":"CAR-T\u2013 and a side order of IgG, to go? \u2013 Immunoglobulin Replacement in Patients Receiving CAR-T Cell Therapy","volume":"38","author":"Hill","year":"2019","journal-title":"Blood Rev"},{"key":"R79-20260925","first-page":"460","article-title":"Hypogammaglobulinemia After Chimeric Antigen Receptor (CAR) T-Cell Therapy: Characteristics, Management, and Future Directions","volume":"10","author":"Wat","year":"2022","journal-title":"The Journal of Allergy and Clinical Immunology: In Practice"},{"key":"R80-20260925","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1182\/bloodadvances.2024015008","article-title":"Characteristics of infections after BCMA-directed CAR T-cell therapy for multiple myeloma: a real-world analysis","volume":"9","author":"Richardson","year":"2025","journal-title":"Blood Adv"},{"key":"R81-20260925","doi-asserted-by":"crossref","first-page":"5485","DOI":"10.1182\/bloodadvances.2023010524","article-title":"Respiratory infections predominate after day 100 following B-cell maturation antigen\u2013directed CAR T-cell therapy","volume":"7","author":"Little","year":"2023","journal-title":"Blood Adv"},{"key":"R82-20260925","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1182\/blood-2017-07-793760","article-title":"Infectious complications of CD19-targeted chimeric antigen receptor\u2013modified T-cell immunotherapy","volume":"131","author":"Hill","year":"2018","journal-title":"Blood"},{"key":"R83-20260925","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1080\/14787210.2021.1855143","article-title":"CAR-T cell therapy and infection: a review","volume":"19","author":"Bupha-Intr","year":"2021","journal-title":"Expert Review of Anti-infective Therapy"},{"key":"R84-20260925","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1182\/bloodadvances.2020004079","article-title":"Infectious complications in patients with relapsed refractory multiple myeloma after BCMA CAR T-cell therapy","volume":"6","author":"Thiruvengadam","year":"2021","journal-title":"Blood Adv"},{"key":"R85-20260925","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood.2019004000","article-title":"How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies","volume":"136","author":"Hill","year":"2020","journal-title":"Blood"},{"key":"R86-20260925","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41408-025-01282-0","article-title":"Effect of Intravenous Immunoglobulin (IVIG) Supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myeloma","volume":"15","author":"Mohan","year":"2025","journal-title":"Blood Cancer J"}],"container-title":["The Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/PPO.0000000000000849","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T20:01:05Z","timestamp":1790366465000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/PPO.0000000000000849"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":85,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/ppo.0000000000000849","relation":{},"ISSN":["1540-336X","1528-9117"],"issn-type":[{"value":"1540-336X","type":"electronic"},{"value":"1528-9117","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"2026-04-19","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-17","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}